Hookipa Biotech   Report issue

For profit Phase 2
Founded: Vienna Austria (2011)

Organization Overview

First Clinical Trial
2016
NCT02798692
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Hookipa Biotech | Hookipa Biotech GmbH

Active Ingredients

Drugs in Phase 2 Trials (4)

hb-101 (2 trials)

hb-201 (2 trials)

hb-301 (1 trial)

hb-302 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Squamous Cell (Phase 2)

Cytomegalovirus Infections (Phase 1)

Oropharyngeal Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 4